12/19/2025
Today marks a meaningful shift in cannabis policy.
The federal move to reclassify cannabis is a step many healthcare professionals, researchers, and patient advocates have worked toward for decades. This change formally acknowledges what science and clinical experience have long shown: cannabis has recognized medical value and does not belong in the most restrictive category of controlled substances.
This reclassification brings tangible benefits. It helps reduce barriers to research, making it easier for scientists to study cannabis and its therapeutic potential. It also has significant implications for cannabis businesses in legal states, including relief from IRS Section 280E. This means state-legal cannabis operators may finally deduct ordinary business expenses, improving financial stability, transparency, and long-term viability.
These shifts matter for patient safety, workforce sustainability, and the overall health of regulated cannabis programs.
At the same time, it’s important to be clear about what this change does not do.
Reclassification does not legalize cannabis. It does not create medical or adult-use programs in states where none exist, nor does it automatically expand patient access. Banking access may improve incrementally, but most financial institutions will remain cautious until additional federal protections are in place.
We’re grateful for progress. Recognition matters. Patients matter.
From a nursing and public health perspective, descheduling cannabis entirely remains the true milestone. Full descheduling would further remove barriers to research, reduce conflicts between state and federal law, and allow healthcare professionals to engage fully in evidence-based education and patient advocacy.
Today, we acknowledge meaningful progress.
Tomorrow, we continue the work.